TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33745119
Drug: Electrolyte maintenance
Normalized name: Truelyte Advanced Hydration Electrolyte Maintenance Solution (Fruit Punch)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte maintenance solution
Study: 33019798
Drug: Gastrodia-uncaria granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrodia-uncaria granules (5 to 10 g twice daily for 4 weeks)
Study: 33019798
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 to 10 g twice daily for 4 weeks)
Study: 33436683
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ranibizumab + focal/grid short-pulse laser)
Study: 32219478
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium bifidum) administered twice a day for 5 weeks
Study: 32219478
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered twice a day for 5 weeks
Study: 32804188
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of regular, oral sustained-release morphine twice daily for 4 weeks (with possibility to increase to 3 times daily after 1 or 2 weeks)
Study: 32804188
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of regular, oral sustained-release morphine
Study: 34648082
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with dose-dense paclitaxel (80 mg/m2 on days 1, 8, and 15), carboplatin (AUC 6.0 mg/mL × min. on day 1), and bevacizumab (15 mg/kg on day 1)
Study: 34648082
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with dose-dense TC-bevacizumab therapy
Study: 33402230
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 5 mg plus promethazine 25 mg (HP)
Study: 33402230
Drug: Intramuscular chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chlorpromazine 100 mg plus haloperidol 5 mg plus promethazine 25 mg (HPC)
Study: 32863100
Drug: TENS associated
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS associated with vocal therapy
Study: 36109142
Drug: OKZ 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ 64 mg once every 2 weeks (q2w)
Study: 36109142
Drug: OKZ 64
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ 64 mg once every 4 weeks (q4w)
Study: 36109142
Drug: OKZ (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ (both dosing regimens)
Study: 33317342
Drug: Jet injector
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injector of insulin glargine (12-18 IU/day)
Study: 35201920
Drug: MitoQ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (20 mg/day)
Study: 33276115
Drug: Tongue scraping
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue scraping (standard treatment)
Study: 34698371
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg plus topical corticosteroids (TCS) as needed
Study: 35731044
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk taste and smell administered together
Study: 33111337
Drug: DWP14012 (fexuprazan)
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 (fexuprazan) 40 mg
Study: 33111337
Drug: DWP14012 (fexuprazan)
Normalized name: fexuprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 (fexuprazan) 80 mg
Study: 33397395
Drug: Dulaglutide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (1.5 mg/day weekly)
Study: 33638769
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (E)
Study: 33571966
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine 8.75 µg/h
Study: 33571966
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine 17.5 µg/h
Study: 33571966
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine 35 µg/h
Study: 33571966
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine 8.75 µg/h and 17.5 µg/h
Study: 34333845
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate 0.5% eye drops
Study: 33173695
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel combined with pressure garment (PG)
Study: 33173695
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheet combined with pressure garment (PG)
Study: 33173695
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel and silicone gel sheet combined with PG
Study: 35172870
Drug: Customized maxillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized maxillary oral appliance (CMOA)
Study: 32267031
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with rose essence (0.2 ml)
Study: 32267031
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with lavender essence (0.2 ml)
Study: 34913883
Drug: Exercise combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise combined with Acceptance and Commitment Therapy (ExACT)
Study: 33318068
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (dose-adjusted 3, 7, or 14 mg)
Study: 33318068
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (initiated at 3 mg)
Study: 32559401
Drug: Crystalloid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalloid infusion
Study: 33992267
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling (DN) plus manual therapy (MT)
Study: 33992267
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) alone
Study: 32265129
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) boost treatment of 19.5 to 21 Gy in 3 fractions (1 fraction per week)
Study: 32265129
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) external beam radiotherapy (EBRT) boost treatment of 32 to 33 Gy in 15 to 16 fractions
Study: 35596784
Drug: Hyperglycaemia (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (oral and intravenous glucose, target blood glucose > 25 mM for 2 hours)
Study: 35596784
Drug: Moxifloxacin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (administered on day 3)
Study: 35596784
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered on day 1)
Study: 33010810
Drug: as-needed budesonide–formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: as-needed budesonide–formoterol 200–6 μg
Study: 33010810
Drug: budesonide maintenance
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide maintenance 200 μg twice daily plus as-needed terbutaline
Study: 33010810
Drug: as-needed terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: as-needed terbutaline 0.5 mg
Study: 35126880
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment As Usual (ETAU)
Study: 35035229
Drug: Suppository Diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository Diclofenac 100mg
Study: 35035229
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (5% Prilocaine/Lidocaine)
Study: 34764195
Drug: High-dose IFNα-2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFNα-2b for one year
Study: 34764195
Drug: High-dose IFNα-2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFNα-2b
Study: 32065311
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene tutoring for CHs and CHns
Study: 35764194
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (individual education in diabetes management, advice on healthy lifestyle, medication regulation by a blinded endocrinologist)
Study: 33682192
Drug: Medication associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication associated diarrhea
Study: 32439229
Drug: ROTEM (thromboelastometry)
Normalized name: METHYL SALICYLATE 35 g in 100 g / MENTHOL 4 g in 100 g / CAPSAICIN 0.038 g in 100 g TOPICAL CREAM [Rotex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTEM (thromboelastometry) guided therapy
Study: 36331685
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate variability biofeedback (HRVB) intervention combined with treatment as usual
Study: 34373214
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment + medication
Study: 34373214
Drug: Arthrocentesis +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis + medication
Study: 35051993
Drug: Control1: No
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control1: No treatment group
Study: 35544042
Drug: rVSVΔG-ZEBOV-GP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSVΔG-ZEBOV-GP vaccine (3 × 105 to 1 × 108 pfu)
Study: 35544244
Drug: rVSVΔG-ZEBOV-GP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSVΔG-ZEBOV-GP vaccine
Study: 35296253
Drug: Dynamic individualized
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic individualized PEEP titration (DV group)
Study: 35951718
Drug: Risuteganib (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risuteganib (1.0 mg intravitreal injection)
Study: 33245129
Drug: Tubaramure program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubaramure program (treatment arms combined)
Study: 35576276
Drug: Microporous tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microporous tape applied to scars for six months, worn twenty-four hours daily, changed every fortnight.
Study: 32553596
Drug: IC injection
Normalized name: WATER,BACTERIOSTATIC INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC injection of CD133+ BMSC
Study: 35247847
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of fish oil concentrate (providing 1.1 g eicosapentaenoic acid (EPA) + 0.8 g docosahexaenoic acid (DHA))
Study: 35247847
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of corn oil
Study: 34545613
Drug: 1 finger‐tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 finger‐tip unit equivalent dose of Hirudoid Cream 0.3% applied twice daily for 28 days
Study: 34545613
Drug: 1/3 finger‐tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/3 finger‐tip unit equivalent dose of Hirudoid Cream 0.3% applied twice daily for 28 days
Study: 34545613
Drug: 1 finger‐tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 finger‐tip unit equivalent dose of Hirudoid Cream 0.3%
Study: 34545613
Drug: 1/3 finger‐tip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/3 finger‐tip unit equivalent dose of Hirudoid Cream 0.3%
Study: 32569087
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in first treatment period
Study: 32569087
Drug: Trial-specific factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial-specific factors (treatment sequence, chance of having placebo treatment)
Study: 35640225
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral weight loss treatment (BT)
Study: 35640225
Drug: Acceptance-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based therapy (ABT) with a focus on PA
Study: 34599401
Drug: Low-energy laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy laser therapy (LLT) plus exercises
Study: 34641941
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) therapy after static stretching
Study: 32433273
Drug: LFD/B-GOS (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFD/B-GOS (1.4 g/d)
Study: 32433273
Drug: Control (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sham diet with placebo supplement)
Study: 35899378
Drug: Rozibafusp alfa
Normalized name: Rozibafusp Alfa
DrugBank: Rozibafusp Alfa (DB19233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozibafusp alfa (n = 26, doses of 70, 140, 210, and 420 mg)
Study: 35899378
Drug: Rozibafusp alfa
Normalized name: Rozibafusp Alfa
DrugBank: Rozibafusp Alfa (DB19233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozibafusp alfa (210 and 420 mg cohorts)
Study: 32654554
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose carbidopa (600 mg/day)
Study: 32654554
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose carbidopa (300 mg/day)
Study: 34990262
Drug: Low-dose ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ara-C (LDAC, n=91)
Study: 34990262
Drug: Augmented high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented high-dose ara-C (HDAC, n=75)
Study: 34990262
Drug: Augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented therapy (AML02-HDAC or AAML0531-ADE + GO)
Study: 35111274
Drug: MPM (paracetamol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPM (paracetamol, ibuprofen, and arm physiotherapy)
Study: 35111274
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication 'as needed' (Control)
Study: 32407137
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) herbal formula, consumed twice daily for 3 months
Study: 35843174
Drug: NAB-PTX (nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAB-PTX (nanoparticle albumin bound paclitaxel) administered via PIPAC at doses escalated from 35 to 140 mg/m2, with three treatments at four-week intervals.
Study: 35843174
Drug: NAB-PTX (nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAB-PTX (nanoparticle albumin bound paclitaxel) administered via PIPAC.
Study: 32600406
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of a nicotine patch (up to 84 mg)
Study: 36258654
Drug: LivingWith® app
Approvals — FDA: no, EMA: no, PMDA: no
Description: LivingWith® app used weekly for 3 months
Study: 32028926
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) delivered via a mobile app (Manaaki) with six intervention modules, personalized feedback, and various engagement features.
Study: 32028926
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) delivered via a mobile app (Manaaki).
Study: 32770685
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FCO2 laser and PRP
Study: 34684862
Drug: Iron-rice (IR)
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rice (IR) drink (15 mg iron/serving) consumed by anemic group (C) for 30 days
Study: 34684862
Drug: Iron-rice (IR)
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rice (IR) drink (27 mg iron/serving) consumed by non-anemic group (D) for 30 days
Study: 34684862
Drug: Iron-rice (IR)
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rice (IR) drink (15 mg iron/serving) consumed by non-anemic group (A) for 30 days
Study: 34684862
Drug: WR drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR drink (2 mg iron/serving) consumed by non-anemic group (A) for 30 days
Study: 32130679
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of ibuprofen/acetaminophen 250/500 mg (two tablets of ibuprofen 125 mg/acetaminophen 250 mg)
Study: 32130679
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of ibuprofen/acetaminophen 250/500 mg with food
Study: 32130679
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of ibuprofen/acetaminophen 250/500 mg in adolescents
Study: 32130679
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of ibuprofen/acetaminophen 250/500 mg in adolescents aged 12-14 years
Study: 32130679
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of ibuprofen/acetaminophen 250/500 mg
Study: 37490268
Drug: CAL/BDP PAD-cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL/BDP PAD-cream
Study: 34271782
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (MgSO4) as intravenous infusion
Study: 34719101
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer light with bi-weekly intradermal PRP (group A)
Study: 32350903
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions (Control)
Study: 34961645
Drug: Conventional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional surgical treatment without CANS
Study: 32445247
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections (ILIs) of triamcinolone acetonide (TA) combined with extracorporeal shock wave therapy (ESWT)
Study: 32445247
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections (ILIs) of triamcinolone acetonide (TA) alone
Study: 32272914
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (300 mg magnesium citrate daily)
Study: 32272914
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (daily)
Study: 34151502
Drug: SciMoCa (secondary
Approvals — FDA: no, EMA: no, PMDA: no
Description: SciMoCa (secondary Monte Carlo dose calculation)
Study: 32666905
Drug: Electronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic treatment register used in the DeWorm3 Project for mass drug administration.
Study: 35042751
Drug: Efpeglenatide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide (4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks)
Study: 32001530
Drug: Intensive vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vincristine dosing
Study: 33940113
Drug: EvoCit (heparin-grafted
Approvals — FDA: no, EMA: no, PMDA: no
Description: EvoCit (heparin-grafted dialyzer with citrate-enriched dialysate)
Study: 33940113
Drug: EvoHep (heparin-grafted
Approvals — FDA: no, EMA: no, PMDA: no
Description: EvoHep (heparin-grafted dialyzer with systemic heparin)
Study: 35149238
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of hyperoxygenated fatty acids (HOFA) solution
Study: 35149238
Drug: Saline physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline physiological solution (non-HOFA)
Study: 32077392
Drug: Olive/Soyabean lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive/Soyabean lipid emulsion (O/S) at a dose of 0.8 g/kg per day for 7 days
Study: 32077392
Drug: 100% Fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% Fish oil (FO) at a dose of 0.4 g/kg per day for 7 days
Study: 38048133
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitor
Study: 33449924
Drug: Annual school-based
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual school-based preventive chemotherapy with praziquantel (40 mg/kg) over four years
Study: 33449924
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment only in the first two years, followed by two years without treatment